Treatment and Managing Medications for PARK19A
At a Glance
PARK19A care is individualized because levodopa responses vary between children. Treatment may include monitored medication, support for dystonia, seizures, and swallowing problems; deep brain stimulation is an exceptional specialist-center option because evidence is very limited.
Managing PARK19A (DNAJC6-related parkinsonism) requires a highly personalized approach. Because this condition is so rare, there is no single treatment that works for everyone. Doctors focus on symptomatic treatment—using medications and procedures to reduce specific symptoms and improve a child’s quality of life [1][2].
The Role of Levodopa
Levodopa (often given as carbidopa/levodopa) is a standard medication for Parkinson’s symptoms. In PARK19A, the response to this medication is often complex and varies significantly between children. Any trial of levodopa must be carefully supervised and individualized by the prescribing specialist.
- Potential Benefits: Some children see partial improvements in their walking (gait), fine motor skills, or generalized muscle spasms (dystonic spells) [3][4].
- Variable Response: Unlike typical adult Parkinson’s, children with severe PARK19A may only have a mild or temporary response to levodopa [5].
- Side Effects and Risks: Reported medication effects that families should monitor for include:
- Dyskinesias: Involuntary, “wiggly” or jerky movements caused by the medication [3].
- Motor Fluctuations: The medication may wear off quickly, leading to “on-off” periods [6].
- Hallucinations and Somnolence: Visual hallucinations or excessive daytime sleepiness [3].
- Adverse Motor Crises: In rare cases, severe dose-related reactions have been reported, such as opisthotonus (severe arching of the back), sustained upgaze (eyes being “stuck” looking upward), and high blood pressure [5]. Never start, stop, or change levodopa without your prescribing specialist.
Deep Brain Stimulation (DBS)
Deep Brain Stimulation (DBS) is a surgical treatment where a “brain pacemaker” is implanted. For children with PARK19A, DBS is not an established treatment and evidence is extremely limited [6].
- The Target: One isolated case report described targeting the internal globus pallidus (GPi) for a patient with severe tremor [6][7].
- Outcomes: This case study of a 15-year-old girl showed tremor reduction [6]. However, DBS is unlikely to address developmental regression, seizures, cognition, or swallowing by itself.
- Considerations: DBS is an exceptional specialist-center consideration, not a usual option [7].
Other Supportive Treatments
Beyond parkinsonism-specific drugs, other therapies are standard for managing the complex symptoms of PARK19A:
- Botulinum Toxin (Botox): Injections can be used to treat focal dystonia (severe muscle tightness). However, injections for drooling or jaw dystonia require assessment by an experienced clinician because they can weaken swallowing or worsen aspiration risk [2][5].
- Seizure Management: If a child develops epilepsy, standard anti-seizure medications are used [3][5].
- Bulbar Support: For children with dysphagia, working with a speech-language pathologist and nutritionist is vital [3][5].
Because children with PARK19A can be very sensitive to medication, any changes to their treatment plan should be made slowly and under close supervision [5].
Common questions in this guide
What is the usual treatment approach for PARK19A?
Can levodopa improve symptoms in a child with PARK19A?
What medication side effects should I watch for with PARK19A?
Could deep brain stimulation help a child with PARK19A?
Can Botox help with dystonia in PARK19A?
What other support may a child with PARK19A need?
Get notified when new evidence is published on Juvenile onset Parkinson disease 19A.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (7)
- 1
DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
Ng J, Cortès-Saladelafont E, Abela L, et al.
Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1357-1368 doi:10.1002/mds.28063.
PMID: 32472658 - 2
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
Niemann N, Jankovic J
Parkinsonism & related disorders 2019; (67()):74-89 doi:10.1016/j.parkreldis.2019.06.025.
PMID: 31272925 - 3
Childhood-onset parkinsonism, dystonia and severe muscle wasting in a Sudanese girl caused by a novel homozygous DnaJ heat shock protein family (heat shock protein 40) member C6 frameshift variant, with an incidental pathogenic breast cancer 1 gene secondary finding: a case report.
Ahmed KAHM, Ahmed RKY
Journal of medical case reports 2026; (20(1)).
PMID: 42897672 - 4
Levodopa responsive-generalized dystonic spells and moaning in DNAJC6 related Juvenile Parkinson's disease.
Mittal SO
Parkinsonism & related disorders 2020; (81()):188-189 doi:10.1016/j.parkreldis.2020.10.046.
PMID: 33181391 - 5
Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism.
Pessoa ALS, Guimarães TG, de Castro Dos Santos D, et al.
Movement disorders clinical practice 2026; doi:10.1002/mdc3.70731.
PMID: 42414182 - 6
Pallidal Deep Brain Stimulation for Tremor Control in a Child with Juvenile DNAJC6-Associated Parkinsonism.
Bernardi K, Valcheva D, Marquez Franco R, et al.
Tremor and other hyperkinetic movements (New York, N.Y.) 2026; (16()):32 doi:10.5334/tohm.1187.
PMID: 42182522 - 7
A Gap Analysis of Deep Brain Stimulation for Childhood-Onset Movement Disorders.
Munoz-Chesta D, Gorodetsky C, Herrington TM, et al.
Movement disorders : official journal of the Movement Disorder Society 2026; doi:10.1002/mds.70389.
PMID: 42544783
This page describes PARK19A treatment options for informational purposes only and does not constitute medical advice. A pediatric neurologist or prescribing specialist should guide levodopa changes, side-effect management, and any consideration of DBS or botulinum toxin.